Pune, India -- (SBWIRE) -- 05/10/2019 -- Our latest research report entitled Cancer Biomarkers Market (by biomolecule type (genetic, epigenetic, metabolic, and proteomic), cancer type (breast, lung, prostate, colorectal, stomach, skin, ovarian, blood cancer), application (diagnostics, prognostics, risk assessment, drug discovery and development), end-users (hospitals, specialty centers, cancer research centers)) provides complete and deep insights into the market dynamics and growth of cancer biomarkers. Latest information on market risks, industry chain structure cancer biomarkers cost structure and opportunities are offered in this report. The past, present and forecast market information will lead to investment feasibility by studying the essential cancer biomarkers growth factors. According to the report, the global cancer biomarkers market is projected to grow at a CAGR of 10.5% over the forecast period of 2018-2024.

Ask for Sample Copy of Research Report with Table of Content @ https://www.infiniumglobalresearch.com/reports/sample-request/1972

Cancer Biomarkers Market: Insight

Cancer biomarkers are biological molecules found in blood, other body fluids, or tissues that are secreted by the cancerous tumor. It is a specific response of the body due to the presence of cancer. Cancer biomarkers include proteins, gene mutations, gene rearrangements, missing genes, and other molecules. Cancer biomarkers have many potential applications including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of progression of the disease. It is used for the diagnosis and prognosis of various types of cancers including liver cancer, breast cancer, ovarian cancer, melanoma, pancreatic cancer, and many more. The use of cancer biomarkers to guide treatment can have both clinical and economic advantages.

Cancer Biomarkers Market: Drivers and Restraints

Cancer is a major public health problem worldwide. The rising occurrence of several types of cancer drives the growth of cancer biomarkers market. The Center for Disease Control and Prevention estimated that 22.9 million adults were diagnosed with cancer in 2016 in the U.S. The growing demand for cost-effective methods for cancer diagnosis boosts the cancer biomarkers market. According to the World Health Organization, the total annual economic cost of cancer was estimated at approximately USD 1.16 trillion. In addition, several countries have a strong government focus on healthcare costs and are implementing cost-effective health technology assessments that contribute to the growth of the cancer biomarkers market. The steady rise in the elderly population and the shift in behavioral patterns such as smoking, consumption of alcohol and lack of physical activity increase the risk of cancer.

However, the high capital investment required for the development and installation of laboratories curtails the growth of cancer biomarkers market. The safety and disposal considerations in specimen collection and storage are the major challenges for the growth of the cancer biomarker market. Moreover, increasing awareness among healthcare professionals and rising demand for personalized medicine is anticipated to provide fruitful opportunities for market growth. Besides, the recent advancements in biologics technologies offer favorable growth opportunities for biomarker-guided testing technologies for cancer treatment.

Ask Discount for the Latest Research Report @ https://www.infiniumglobalresearch.com/reports/request-discount/1972

Cancer Biomarkers Market: Regional Analysis

Geographically, North America is the dominant region in the cancer biomarkers market. The high rate of adoption of advanced medical technologies primarily drives the cancer biomarkers market in the North America region. The busy lifestyle increases the risk of cancer in the North America region, thus promoting the growth of the cancer biomarkers market in this region. Europe is the second largest region in the portable medical devices market as the countries in this region such as New Zealand, Ireland, and France have the highest cases of cancer. Asia Pacific regions are set to grow with an incredible pace in the cancer biomarkers market over the forecast period owing to the increasing aging population and the increasing occurrences of cancer in this region.

Cancer Biomarkers Market: Segmentation

The report on global cancer biomarkers market covers segments such as biomolecule type, cancer type, application, and end-users. On the basis of biomolecule type, the sub-markets include genetic, epigenetic, metabolic, and proteomic. On the basis of cancer type, the sub-markets include breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, skin cancer, ovarian cancer, blood cancer, and others. On the basis of application, the sub-markets include diagnostics, prognostics, risk assessment, drug discovery and development, and others. On the basis of end-users, the sub-markets include hospitals, specialty centers, and academic and cancer research centers.

Browse Detailed TOC, Description, and Companies Mentioned in Report @ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-cancer-biomarkers-market

Cancer Biomarkers Market: Competitive Landscape

The report provides profiles of the companies in the market such as F. Hoffmann-La Roche Ltd, Abbott Laboratories, GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc, Becton, Dickinson and Company, Hologic, Inc., Genomic Health, Inc, Agilent Technologies, Inc., and Illumina, Inc.

Report Findings

1. Drivers

- Increasing Occurrences of Several Types of Cancers.

- Increasing Advancements in Biologics Technologies.

2. Restraints

- High Capital Investment.

- Safety and Disposal Considerations in Specimen Collection and Storage.

3. Opportunities

- Increasing Awareness Among Healthcare Professionals.

- Rising Demand for Personalized Medicine.